Detalhe da pesquisa
1.
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2.
J Pharmacol Exp Ther
; 373(2): 220-229, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094296
2.
Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Drug Metab Dispos
; 46(8): 1200-1211, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739809
3.
Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Drug Metab Dispos
; 45(4): 390-398, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28167538
4.
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Drug Metab Dispos
; 43(10): 1417-29, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26180127
5.
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Drug Metab Dispos
; 43(1): 54-62, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25349124
6.
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Xenobiotica
; 45(1): 45-59, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034009
7.
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
J Pharmacol Exp Ther
; 351(1): 67-76, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25073473
8.
Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Drug Metab Dispos
; 41(2): 343-52, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23129213
9.
Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
Drug Metab Dispos
; 41(6): 1285-94, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23557746
10.
Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
CPT Pharmacometrics Syst Pharmacol
; 12(10): 1461-1472, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667529
11.
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs.
Clin Pharmacol Ther
; 113(5): 1058-1069, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36524426
12.
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Cell Chem Biol
; 30(10): 1191-1210.e20, 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37557181
13.
Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
J Pharmacol Exp Ther
; 340(3): 549-57, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22129595
14.
Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.
Bioorg Med Chem Lett
; 22(24): 7605-9, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23116892
15.
Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
CPT Pharmacometrics Syst Pharmacol
; 11(1): 55-67, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34668334
16.
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Mol Cancer Ther
; 21(1): 3-15, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34737197
17.
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
J Pharmacol Exp Ther
; 338(3): 964-73, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21680888
18.
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Drug Metab Dispos
; 39(3): 383-93, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21098644
19.
A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels.
Clin Transl Sci
; 14(4): 1412-1422, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742770
20.
Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
CPT Pharmacometrics Syst Pharmacol
; 10(12): 1485-1496, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34729944